Effects of ovarian stimulation on serum concentrations of lipids and ketone bodies in patients undergoing IVF/ICSI treatment;Effekte der ovariellen stimulation auf die serumkonzentrationen von lipiden und ketonkörper bei patientinnen unter IVF-/ICSI-behandlung

Zentralblatt fur Gynakologie

Volumn 126, Issue 2, 2004, Pages 67-72

  Hammadeh, M E ^a   Munz, W ^a   Meisinger, M ^a   Herrmann, W ^b   Georg, T ^a   Rosenbaum, P ^a   Schmidt, W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

IVF ICSI; Ovarian stimulation; Serum concentrations of lipids and ketone bodies

Indexed keywords

2 OXOGLUTARIC ACID; 3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; CHOLESTEROL; ESTRADIOL; GONADORELIN DERIVATIVE; GOSERELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN MENOPAUSAL GONADOTROPIN; KETONE BODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT FOLLITROPIN; TRIACYLGLYCEROL; TRIPTORELIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LIPID BLOOD LEVEL; OVULATION INDUCTION; PATIENT MONITORING; THROMBOSIS; TREATMENT OUTCOME;

3-HYDROXYBUTYRIC ACID; ACETOACETATES; ADULT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; FERTILIZATION IN VITRO; HUMANS; KETOGLUTARIC ACIDS; KETONE BODIES; LIPIDS; OVULATION INDUCTION; SPERM INJECTIONS, INTRACYTOPLASMIC; TRIGLYCERIDES;

EID: 2442715118     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-816269     Document Type: Article

References (26)

1. Abbott RD, Wilson PW, Kannel WP, Castelli WP. High density lipoprotein cholesterol, total cholesterol sreening and myocardial infarction. The Framingham Study. Arteriosclerosis 1988; 8: 207-211
2. Basdevant A. Steroids and Lipid Metabolism: Mechanism of action. Int J Fertil 1992; 37: 93-97
3. Berg GA, Siseles N, Gonzalez AI, Ortiz OC, Tempone A, Wikinski I. Higher values of hepatic lipase activity in postmenopause: relationship with atherogenic intermediate density and low density lipoproteins. Menopause 2001; 8: 51-57
4. Bergmeyer HU, Bernt E. Methoden der enzymatischen Analyse. Verlag Chemie, Weinheim 1974
5. Bush TL, Miller VT. Effects of pharmacologic agents used during the menopause. In: Mishell DR (ed). Menopause: Physiology and Pharmacology. Year Book Medical Publishers, Chicago 1987, 187-208
6. Cheung MD, Albers JJ. The measurement of apolipoprotein AI and AII levels in men and women by immunoassay. J Clin Invest 1977; 60: 43-50
7. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, Guyene TT, Mairon N, Corvol P, Guy-Grand et al. Biological effects of estradiol 17-β in postmenopausal women: Oral versus percutaneous administration. J Endocrinol Metab 1986; 62: 536-541
8. Diedrich K. Gynäkologie und Geburtshilfe. Springer-Verlag, Berlin, Heidelberg 2000
9. Freedman DS, Gruchow HW, Anderson AJ, Rimm AA, Barboriak JJ. Relation of triglyceride levels to coronary artery disease: the Milwaukee Cardiovascular Data Registry. Am J Epidemiol 1988; 127: 1118-1130
10. Friedwald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low density-lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
11. Gordon T, Castelli WP, Hjortland C, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med 1977; 62: 707-714
12. Haines CJ, Cheung L, Lam CW. Changes in atherogenic lipids and lipoproteins during natural and hyperstimulated cycles in healthy women. Fertil Steril 1997; 68: 231-235
13. Kannel WB, Castelli WP, Gordon T, Mc Namara PM. Serum cholesterol, lipoproteins, and the risk of coronary diseases: The Framingham study. Ann Intern Med 1971; 74: 1-12
14. Kannel WB, D'Agostino RB, Belanger AJ. New insights on cholesterollipoprotein profiles: The Framingham Study. Presented at the 61st Scientific Sessions of the AHA, November 1988
15. Karakas SE, Khilnani S, Divens C, Almario R, Jen KL. Changes in plasma lipoproteins during lipolysis in vivo in the hypertriglyceridemic state. Am J Clin Nutr 1994; 59: 378-383
16. Kopera H. Stoffwechselwirkungen oraler Kontrazeptiva. WMW 1987; 18: 455-459
17. Kuhl H. Metabolische Effekte der Ostrogene und Gestagene. Gynäkologe 1997; 30: 357-369
18. Nikkila EA. Plasma lipoprotein transport system: effects of sex steroids. In: Van Keep PA, Kopera H (eds). Oral contraceptives and lipoproteins. International Health Foundation, Brussels 1983; 13-24
19. Redmond GP. Lipids and women's health. Springer Verlag, New York 1991
20. Seed M, Doherty E, O'Connor B, Reaveley D. Effect of high endogenous oestrogen level on lipoprotein concentration. J Endocrinol 1991; 131: 73
21. Seidel J, Hägele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-1080
22. Sorva R, Kuusi T, Dunkel L, Taskinen MR. Effects of endogenous sex streoids on serum lipoproteins and postheparin plasma lipolytic enzymes. J Clin Endocrinol Metab 1988; 66: 408-413
23. Tadmor OP, Kleinman Y, Barr I, Gal M, Brooks BA, Diamant YZ. Side effects of ovarian hyperstimulation: Hormonal and lipid profile changes. Int J Fertil 1994; 39: 105-110
24. Tikkanen MJ, Kuusi T, Nikkila EA, Sipinen S. Postmenopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins. A review. Maturitas 1986; 8: 7-17
25. Wahlefeld AW, Bergmeyer HU. Methods of enzymatic analysis. 2nd English ed. New York 1974
26. Williamson DH, Mellanby J. Methoden der enzymatischen Analyse. Verlag Chemie, Weinheim 1974; 1883-1886